Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

3.450 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fulcrum Therapeutics Inc

< Previous 1 2 3 4 Next >
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
Analyzing Fulcrum Therapeutics's Unusual Options Activity
On Tuesday, shares of Fulcrum Therapeutics (NASDAQ:FULC) ... 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CohBar (NASDAQ:CWBR) shares incr... 
Via Benzinga
FULC Stock: The Trial News Sending Fulcrum Therapeutics Skyrocketing
Shares of FULC stock are skyrocketing higher today on reports of positive results for the company's sickle cell treatment trial. 
Via InvestorPlace
Mid-Afternoon Market Update: 3D Systems Surges On Upbeat Earnings; Katapult Shares Drop
Toward the end of trading Tuesday, the Dow traded up 0.49% to 35,274.95 while the NASDAQ fell 0.41% to 14,799.03. The S&P also rose, gaining 0.18% to 4,440.12. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fulcrum Therapeutics Shares Are Soaring Today
Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed... 
Via Benzinga
Fulcrum Stock Nearly Triples — Why Shares Went Gangbusters On Sickle Cell Drug
Fulcrum Therapeutics unveiled positive results for its sickle cell disease drug, and the biotech stock more than doubled to a 13-month high. 
Via Investor's Business Daily
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Mid-Day Market Update: Crude Oil Rises Over 3%; comScore Shares Plummet
Midway through trading Tuesday, the Dow traded up 0.37% to 35,231.28 while the NASDAQ fell 0.62% to 14,767.78. The S&P also fell, dropping 0.01% to 4,432.24. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today
A positive trial readout suggests the company's new drug discovery engine has more potential than expected. 
Via The Motley Fool
Mid-Morning Market Update: Markets Open Higher; Sysco Tops Q4 Views
Following the market opening Tuesday, the Dow traded up 0.47% to 35,266.74 while the NASDAQ rose 0.04% to 14,866.20. The S&P also rose, gaining 0.28% to 4,444.54. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study
Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3... 
Via Benzinga
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Brickell Biotech (NASDAQ:BBI) stoc... 
Via Benzinga
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.